Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study

Citations Over TimeTop 10% of 2007 papers

Abstract

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.

Related Papers

• → Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors(2007)121 cited
• → Is it safe to switch between efavirenz and nevirapine in the event of toxicity?(2007)44 cited
• → Assessment of Drug-Drug Interactions Between Tenofovir Disoproxil Fumarate and the Nonnucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz in HIV-Infected Patients(2005)24 cited
• → Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children(2008)20 cited
• → Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy(2014)10 cited